Abstract
Introduction: Implantable left ventricular assist devices (LVADs) benefit patients awaiting cardiac transplantation (OHT) or as destination therapy, but patients receiving currently approved devices still experience serious adverse events. The VentrAssist™ LVAD is a bearingless 3rd generation rotary device designed to increase durability and reliability. Here, we review the survival, adverse events (AE) and quality of life (QoL) of the initial US experience of this device as a bridge to transplant.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
